Drug major Glenmark Pharmaceuticals, which recently decided to spin off its innovation business into a separate company in the US, has roped in Alessandro Riva, a Gilead and Novartis veteran, as chief executive officer (CEO).
Riva, who joined Gilead about two years back, is leaving his post as executive vice-president of oncology.
His appointment as CEO of Glenmark’s innovation business is effective from April 2.
In mid-February, Glenmark said it has received an in-principle approval from its board to spin off the innovation business into a new company that would be headquartered in the US. The Paramus (New Jersey) company would be a